"CANCER MOONSHOT BIOBANK ONLINE CATALOG.

国家癌症研究所(NCI)的癌症登月计划旨在加速通过“蓝丝带专家小组”(BRP)确定的关键战略领域的癌症研究。BRP建议的核心内容包括通过解决关键的科学问题来加快癌症研究的进展。还包括在全国范围内参与代表美国人口多样性的患者研究的需要。NCI发起了癌症登月生物库，通过为关键研究工作收集和分发生物标本来加速研究。生物库将与1000多名接受标准护理治疗的癌症患者接触，进行纵向生物样本收集。根据BRP的建议，癌症患者将从美国各地医疗机构的不同参与人群中登记参加这项研究。生物样品将分发给合格的科学家，以加快研究进展。Biobank计划与Leidos Biomedical，Inc.(LBR)密切合作，将与社区医院和其他医疗机构合作，指定为生物标本来源站点(BSS)，以吸引和同意符合条件的参与者，收集生物标本和相关临床数据；与中央生物标本核心资源(BCR)合作，支持生物标本的收集、加工和存储活动，并执行病理质量控制；与LBR的分子表征(MOCHA)实验室合作，进行临床肿瘤分子表征分析，并将结果返回给患者及其医生；通过在线目录系统向研究人员提供生物标本和相关数据，以加快癌症研究进展。临床结果返回、专门的患者和提供者参与度(PPE)网站、电子知情同意、本地参与者参与度项目以及嵌入的伦理、法律和社会问题子研究将共同支持患者和提供者参与该计划。

The National Cancer Institute’s (NCI) Cancer Moonshot Program is intended to accelerate cancer research in key strategic areas that were identified through a “Blue Ribbon Panel” (BRP) of experts. Core elements of the BRP recommendations include accelerating progress in cancer research by addressing critical scientific questions. Also included is the need for nationwide participation in research by patients that represent the diversity of the U.S. population. NCI has initiated the Cancer Moonshot Biobank to accelerate research through the collection and distribution of biospecimens for key research efforts. The Biobank will engage with over one thousand cancer patients, being treated with standard-of-care therapies, for longitudinal biospecimen collection. In keeping with the BRP recommendations, the cancer patients will be enrolled into the study from a diverse participant population engaged at medical institutions throughout the U.S. The biospecimens will be distributed to qualified scientists to accelerate research progress. The Biobank program, working closely with Leidos Biomedical, Inc. (LBR), will partner with community hospitals and other medical institutions, designated as Biospecimen Source Sites (BSS), to engage and consent eligible participants and collect biospecimens and associated clinical data; work with a central Biospecimen Core Resource (BCR) to support biospecimen collection, processing and storage activities and perform pathology quality control; work with LBR’s Molecular Characterization (MoCha) lab to perform clinical tumor molecular characterization assays and return results to patients and their physicians; and make the biospecimens and associated data available through an online catalog system to researchers to accelerate cancer research progress. Return of clinical results, a dedicated Patient and Provider Engagement (PPE) website, electronic informed consent, local participant engagement projects, and an embedded ethical, legal and social issues sub-study will together support patient and provider engagement in the program.